Connect with us


Simris Alg interim report January-September 2022




  • Net revenue decreased by 84% to SEK 316k (1 971k).
  • Personnel & other external costs decreased by 21% to SEK -4 629k (-5 849k).
  • EBITDA improved by 37% to SEK -4 471k (-7 148k).
  • EBIT/ Operating result improved by 43% to SEK -6 115k (-10 701k).


  • Net revenue increased by 19% to SEK 3 762k (3 160k).
  • Personnel & other external costs decreased by 33% to SEK -12 403k (-18 404k).
  • EBITDA improved by 48% to SEK -11 941k (-19 939).
  • EBIT/ Operating result improved by 40% to SEK -15 026k (-25 021k).


  • On July 20, 2022, Simris elected to terminate its arrangement with Mangold Fondkommission AB as Certified Advisor and for liquidity services. On the same day Simris appointed Amudova AB as its new Certified Advisor.
  • Simris published a letter from CEO on Aug 4 August 2022.
  • On 25th August 2022, The Brand Laboratories, a company associated with the Simris Chairman, Steven Schapera, provided a loan facility of up to €1m.
  • Simris Alg completed its purchase of 100% of the shares in Cyano Biotech GmbH on 25 August 2022.
  • As part of the Agreement to purchase 100% of the shares of Cyano Biotech, Simris completed a directed share issue to Dr Dan Enke and Dr Heike Enke on 7 September 2022.


  • No significant events to report after the end of Q3.


My objective for Q3 was to lay down a robust foundation for future sales revenue, and to complete the successful integration of Cyano Biotech GmbH, into the Simris structure. On the revenue front, the team has made great progress towards the December launch of our new Food Supplement products, improving the biosecurity of our production, and valorising additional extracts for B2B sales. In acquiring Cyano Biotech we have become pioneers in the field of Antibody Drug Conjugate (ADC)* medicines, providing drug developers with an entirely unique proposition for a next generation of ADC payloads produced by cyanobacteria. We now have our own R&D laboratories and hold broad patents covering a novel technology platform that gives us an accelerated entrance into the lucrative BioPharma space. I have a very clear view of where I want Simris to be in the next 5 years and am immensely proud that we are considerably closer to those objectives than we were just a few months ago when I began my appointment.

Generating sustainable sales revenue has been the biggest challenge for Simris throughout its history. This is why my top priority since joining in May, has been to build strong sales platforms for the short, medium, and long-term.

Towards the end of Q2, we initiated multiple projects aimed at building these platforms and much progress has been made during Q3. These projects are: (1) launching an improved range of microalgae-based food supplements; (2) enhancing the biosecurity and cultivation conditions of production to reliably increase product quality and yields; (3) identify and extract additional high-value compounds from our biomass as ingredients in B2C products or for sale to B2B customers.

I expect that our hard work will begin to show results in Q4, when we launch our new range of food supplements. The other projects will increasingly deliver revenue and margin throughout the first half of 2023.

Since acquiring Cyano Biotech in August, we have also invested considerable time to develop our understanding of their science and to build relationships with their target customers i.e., drug development companies. Importantly, these conversations are showing great promise.


Data from Amazon US confirms that more than 4m packs of Omega-3 are sold monthly from their marketplace. The potential for an attractively branded and reasonably priced algal Omega-3 is thus significant. Having studied trends in the existing market, the Team decided that a completely fresh approach was needed to unlock this potential.

The new concept is aimed both at converting those currently consuming Omega-3 from fish, to taking Omega-3 from algae, as well as winning over existing consumers of algal Omega-3.

Product: The capsules will contain twice as much EPA and DHA, and yet will be half the size of our historical product. This makes them much easier to swallow, an important factor for about 50% of US consumers and more than 60% of German consumers.**

Packaging: Capsules will be sold in a refill pouch, which is used to refill a Simris-branded storage jar. The storage jar is provided in a Starter Pack, along with two refill pouches. This approach minimises packaging inputs, facilitates low-cost shipping, reduces risk of breakage and is more environmentally responsible.

Price: By using less packaging we reduce direct packaging costs as well as indirect costs such as shipping and damages. This enables us to set a more accessible price, still with healthy margins, to drive volume sales.

Distribution: For the first time, Simris Omega-3 products can be sold into all major markets. In December we will begin selling directly to US consumers from Amazon US, and to Swedish consumers from our own web shop. The plan is to roll-out the range to new markets, with a focus on e-commerce and pharmacies in 2023.


Following with my appointment as CEO, I initiated a comprehensive risk review of Simris operations. As a result, it became clear that the single biggest production risk was biosecurity. During Q3 we engaged external consultants to conduct an independent audit of the company’s approach to biosecurity. Progress has already been made in updating our standard operating procedures (SOP’s), and in making the necessary investments in our production facility. These improvements reduce the risk of contamination as well as providing additional alerts when parameters such as temperature, pH, salinity etc are moving outside of the optimal range.

As expected, following an audit by LRQA at the end of October, Simris has once again been certified for the production and sale of food supplements under the criteria defined by Svensk Egenvård.  

Over this winter we will conduct trials aimed at establishing the optimal conditions for (1) biomass growth and (2) production of Fucoxanthin. To be able to conduct these trials we have moved one of our smaller photobioreactors into a closed room where we can control growth conditions (light &, heat) more closely. Results from these trials will help us to increase yields in 2023 and give us vital insights into the future of our production under the GMP certification required for the production of pharmaceutical products.


Historically, Simris has either extracted only EPA from its biomass or sold biomass to customers for them to process and extract molecules of interest.

At the start of Q3 we changed our mindset and set ourselves the challenge to be able to extract and sell multiple high value molecules/ products from the same biomass. Over the past three months we have developed a process to produce an oleoresin extract rich in Fucoxanthin after already having extracted EPA oil using CO2.

Studies have demonstrated Fucoxanthin to offer potential health benefits for the prevention of chronic diseases, including cancer, obesity, diabetes mellitus, and liver disease. Fucoxanthin is therefore a high value molecule, already well known to us as it was the target molecule within the biomass Simris sold B2B during 2021 and in Q1 of this year.

This opens up the potential to create new consumer products containing Fucoxanthin and to sell a Fucoxanthin rich oil/ oleoresin to B2B customers. Further work is planned through Q4 and into Q1 of next year to (1) define additional Fucoxanthin products; (2) confirm their stability/ shelf-life and (3) establish further molecules of interest/ products that can be produced from the same biomass, for example novel ingredients for cosmetics.


Following our acquisition of Cyano Biotech, I attended the world’s biggest Antibody Drug Conjugate* (ADC) conference at the start of September. Having talked with dozens of experts in the ADC field during and after this event, I am even more convinced that Simris will generate significant revenue from our ADC technology in the coming years.

Drug developers are looking for novel payloads that can be used to develop the next generation of cancer drugs. Whilst still in the pre-clinical phase, Simris now holds a library of cyanobacterial toxins which will provide a pipeline of novel ADC payloads. We also hold a broad patent covering the method by which our payloads are produced. The methodology offers significant potential for the modification of payloads to be both highly potent and highly specific in killing only cancer cells at extremely low concentrations. Achieving this will drastically improve the quality of life of cancer patients undergoing treatment.

Agreements between drug developers and companies offering payloads include up-front payments to license the technology towards a specific target, milestone payments and royalties. For payloads gaining regulatory approval, such agreements can be worth hundreds of millions of dollars.

With our newly acquired library of cyanobacterial strains and payload classes, and as the only company growing ready to conjugate ADC payloads, Simris is unique within the ADC field. Whilst it is still early days, I am encouraged by the interest we have already been able to generate and from the discussions we are currently engaged in with drug developers. 

Through the acquisition of Cyano Biotech, Simris now has its own Research & Development (R&D) laboratories with an in-house R&D team, based in Berlin. As a result, we have cancelled our cooperation with the University of Anhalt, and this is estimated to save Sirmis around €100k a year.

The founders of Cyano Biotech are now our CSO’s. Dr Dan Enke is CSO for ADC Technology, and Dr Heike Enke is CSO for all non-ADC Technology.


Simris has made big steps towards profitability this year. Year to date Sales Revenues are up 19% and on a like for like basis, excluding one-time costs in 2021, EBIT is up 3.3MSEK. This has been achieved through tight cost control whilst building the future sales platforms.

I would like to take this opportunity to thank you for your continued support of Simirs as we take the steps that will lead us towards a profitable future.

The report is published on Simris Algs website:

For more information contact:
Julian Read
CEO Simris Alg AB
Email: [email protected]
Mobile: +46767888212

This information is information that Simris Alg AB is obliged to make public according to the EU’s market abuse regulation. This information was provided by the above contact person for publication on 2022-11-09 at 08:00 AM CEST.

Simris Alg is a biologics company identifying high value, natural, biologically active compounds found in microalgae and cyanobacteria to extract for applications in skincare, nutrition, and biopharmaceuticals. The company sustainably grows microalgae and cyanobacteria at industrial scale within its photobioreactor facility whereby conditions are optimized for production of these high-value compounds.

Simris Alg’s shares are traded on the Nasdaq First North Growth Market with the short name SIMRIS and ISIN code SE0008091664. Certified Adviser is Amudova AB, telephone: 08-546 017 58, email: [email protected]

Continue Reading
Click to comment

Leave a Reply

Din e-postadress kommer inte publiceras. Obligatoriska fält är märkta *


Nordea Bank Abp: Återköp av egna aktier den 05.12.2022




Nordea Bank Abp
Börsmeddelande – Förändringar i återköpta aktier
05.12.2022 kl. 22.30 EET

Nordea Bank Abp (LEI-kod: 529900ODI3047E2LIV03) har den 05.12.2022 slutfört återköp av egna aktier (ISIN-kod: FI4000297767) enligt följande:

Handelsplats (MIC-kod)

Antal aktier

Viktad snittkurs/aktie, euro*, **

Kostnad, euro*, **


260 000


2 626 052,00


240 000


2 420 336,96


36 000


 362 819,55


240 000


2 416 602,28


28 000


 282 816,90


 804 000


8 108 627,70

* Växelkurser som använts: SEK till EUR 10,9185 och DKK till EUR 7,4371
** Avrundat till två decimaler

Den 18 juli 2022 tillkännagav Nordea ett program för återköp av egna aktier till ett värde av högst 1,5 md euro med stöd av det bemyndigande som gavs av Nordeas ordinarie bolagsstämma 2022. Återköpet av egna aktier utförs genom offentlig handel i enlighet med Europaparlamentets och rådets förordning (EU) nr 596/2014 av den 16 april 2014 (marknadsmissbruksförordningen) och Kommissionens delegerade förordning (EU) 2016/1052.

Efter de redovisade transaktionerna innehar Nordea 11 832 125 egna aktier för kapitaloptimeringsändamål och 6 073 651 egna aktier för ersättningsändamål.

Uppgifter om respektive transaktion finns som en bilaga till detta meddelande.

För Nordea Bank Abp:s räkning,
Citigroup Global Markets Europe AG

För ytterligare information:

Matti Ahokas, chef för investerarrelationer, +358 9 5300 8011
Group Communication, +358 10 416 8023 eller [email protected]

Continue Reading


”Insikter om hot och våld” Del 2: Ett nytt, hårdare samtalsklimat




Vad som många har en diffus känsla av stämmer – samtalsklimatet mellan medborgare och samhällets företrädare HAR blivit hårdare. Detta är ett vetenskapligt belagt faktum och det finns en tydlig koppling till hur samtalstonen på nätet har utvecklats. 

Måns Svensson är professor i rättssociologi, vilket förenklat kan beskrivas som kunskapen om hur sociala normer samspelar med lagstiftningen. Under senare tid har Svensson forskat kring utvecklingen av näthat och hur det påverkat kommunikationen mellan allmänhet och olika samhällsföreträdare, exempelvis förtroendevalda, journalister, lärare och vårdanställda.  

– Den här typen av ogillande som samhällets representanter utsätts för visar att den sociala kontrollen har förändrats i grunden, vilket är ett resultat av hur vi kommunicerar online. Vi har tillgång till varandra och kan uttrycka ogillande på ett sätt som är helt nytt. 

Intervjun med Måns Svensson är del två i Säker Vårdmiljös intervjuserie ”Insikter om hot och våld”. Seriens ambition är att lyfta fram insikter, perspektiv och lärdomar på ett ämne som tyvärr blir alltmer aktuellt.  

Du hittar filmerna i serien här:

Säker Vårdmiljö startar under hösten även ett kunskapsnätverk som fokuserar på problematiken med hot och våld. Intresserad? Anmäl dig här. 


Continue Reading


Återköp av aktier i MTG under vecka 48, 2022




Från 28 november till 2 december 2022 har Modern Times Group MTG AB (publ) (LEI-kod 549300E8NDODRSX29339) (“MTG”) återköpt sammanlagt 166 437 egna aktier av serie B (ISIN-kod: SE0018012494) inom ramen för det återköpsprogram som styrelsen infört i syfte att leverera värde till bolagets aktieägare och optimera kapitalstrukturen.

Återköpen är en del av det återköpsprogram om maximalt 4 618 818 aktier till ett sammanlagt belopp om högst 400 miljoner kronor som MTG tillkännagav den 25 oktober 2022. Återköpsprogrammet löper från den 27 oktober 2022 och fram till årsstämman 2023 och genomförs i enlighet med EU:s Marknadsmissbruksförordning (EU) nr 596/2014 (”MAR”) och Kommissionens delegerade förordning (EU) nr 2016/1052 (”Safe harbour-förordningen”). Syftet med återköpsprogrammet är att leverera värde till aktieägare och att optimera kapitalstrukturen. Avsikten är att MTG:s aktiekapital ska nedsättas genom en indragning av återköpta aktier.

Aktier av serie B i MTG har återköpts (i kronor) enligt följande:

Datum Aggregerad daglig volym (antal aktier) Viktat genomsnittspris per dag (SEK) Totalt dagligt transaktionsvärde (SEK)
2022-11-28 35 587 83,0867 2 956 806,39
2022-11-29 35 000 83,0586 2 907 051,00
2022-11-30 33 851 82,3301 2 786 956,22
2022-12-01 35 149 82,8424 2 911 827,52
2022-12-02 26 850 83,7622 2 249 015,07

Samtliga förvärv har genomförts på Nasdaq Stockholm av Nordea Bank Abp för MTG:s räkning. Efter ovanstående förvärv uppgår MTG:s innehav av egna aktier per den 2 december 2022 till 3 347 283 aktier av serie B och 6 324 343 aktier av serie C. Det totala antalet aktier i MTG uppgår till 134 035 940.

Fullständig information om de genomförda transaktionerna enligt artikel 5.3 i MAR och artikel 2.3 i Safe harbour-förordningen biläggs detta pressmeddelande.

För mer information:

Anton Gourman, VP Communications and IR
Direkt: +46 73 661 8488, 
[email protected]

Följ oss: / Twitter / LinkedIn


MTG (Modern Times Group MTG AB (publ.)) ( är en internationell mobilspelskoncern som äger och driver spelutvecklare med globalt populära titlar som sträcker sig över en bred uppsättning genrer inom casual- och mid-core-spel. Koncernen fokuserar på att accelerera portföljbolagens tillväxt och stödja grundare och entreprenörer. MTG är en aktiv aktör i den pågående konsolideringen av spelindustrin och en strategisk köpare av gamingbolag världen runt. Vi kommer från Sverige men har en internationell kultur och globalt fotavtryck. Våra aktier är noterade på Nasdaq Stockholm under symbolerna MTGA och MTGB.

Continue Reading


Copyright © 2017 Zox News Theme. Theme by MVP Themes, powered by WordPress.